CSCX Cardiac Science Corp (MM)

BOTHELL, Wash., June 29 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, today introduced the remaining versions of software required for the recall first announced in November, 2009.

(Logo: http://photos.prnewswire.com/prnh/20080306/AQTH510LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

The software will enhance the AEDs' self-test capabilities and improve detection of a rare component-related issue in certain AEDs manufactured between August, 2003 and August, 2009. The company announced a recall on these AEDs on November 13, 2009. The affected models include Powerheart 9300A, 9300C, 9300D, 9300E, 9300P, 9390A, 9390E, and CardioVive 92531, 92532, and 92533 devices.

The software update is a mandatory step for customers possessing these affected devices. The software and update instructions (available in 36 languages) can be downloaded at http://www.cardiacscience.com/AED175. Customers with affected AEDs will be notified by letter regarding the update. Customers with questions may call or email the company at 877.901.1788 or AED175@cardiacscience.com.

"This release completes the software development initiative associated with our November, 2009 recall," said Cardiac Science President and CEO Dave Marver. "The software update for a significant portion of affected AEDs was released in March and we're pleased to now release the update for the remaining device population. We encourage users with an affected AED to install the update as soon as possible."

As before, the company advises customers to follow the normal testing and maintenance procedures found in the Operator and Service Manual.

If an AED is not rescue ready (the indicator is red), customers should contact the company immediately at 425.402.2000 (option 1) within the United States. Outside the US contact +44.161.926.0011 or the local Cardiac Science representative.

This release represents the completion of the company's software development efforts related to the previously announced recall. The costs associated with this software release are included in the charges previously announced by the Company.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The word "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to, the scope, capabilities, and effectiveness of the software update. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB, YouTube at http://www.youtube.com/user/CardiacScience.

For more information,

LOGO: http://www.cardiacscience.com/images/main_logo.gif

CSCX-F

SOURCE Cardiac Science Corporation